1787.9000 17.50 (0.99%)
NSE Jul 10, 2026 15:31 PM
Volume: 146.8K
 

1787.90
0.99%
Emkay
Ipca’s 4QFY26 EBITDA was ahead of our expectations (broadly in line with the consensus’). The beat was driven by higher overall sales, a marginally higher gross margin, as well as lower staff costs.
Ipca Laboratories Ltd. is trading above all available SMAs
More from Ipca Laboratories Ltd.
Recommended